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Summary The biochemical basis of multidrug-resistant (MDR) phenotype has been investigated in drug-
resistant sublines independently obtained in our laboratories by single step doxorubicin (DOX) selection of
LoVo, DLD1, and SW948 human colon carcinoma (HCC) cell lines. All the chemoresistant sublines have been
found to be cross-resistant to DOX, actinomycin-D (ACT-D) and vincristine (VCR) but not to cis-diammine-
dichloroplatinum (CDDP), and have exhibited an increased expression level of mdrl mRNA and gpl70
glycoprotein. Comparative analyses in drug-resistant and sensitive cells of resistance index, extracellular and
intracellular equitoxic DOX concentrations, and mdrl gene products expression have indicated that MDR
phenotype is a multifactorial phenomenon due to different and possibly independent biochemical mechanisms
which cooperate, in varying degrees from cell line to cell line, in conferring cellular chemoresistance.
In vitro derived drug-resistant cell lines frequently show a
typical wide spectrum of chemoresistance to many struc-
turally and functionally unrelated drugs (Ling et al., 1983;
Kaye, 1988). The multidrug-resistant (MDR) phenotype in
human cells is thought to be primarily consequent upon the
increased expression of the mdrl gene (Riordan et al., 1985;
Shen et al., 1986; Chin et al., 1989) which encodes for a
plasma transmembrane glycoprotein of 170 kD (gp 170)
(Kartner et al., 1983; Chen et al., 1986). gpl7O causes
reduced intracellular drug accumulation through an energy-
dependent active drug efflux (Dano, 1973; Skovsgaard, 1978).
Recent studies, however, have reported that biochemical
phenomena, unrelated to increase in gpl7O expression and/or
function, also contribute in conferring the MDR phenotype
(Goldenberg et al., 1986; Slovak et al., 1988; Ferguson et al.,
1988; Cole et al., 1989; Reeve et al., 1989; Toffoli et al.,
1989a).
In order to define the molecular basis of the MDR pheno-
type in human colon carcinoma (HCC) cells, we have derived
MDR sublines from LoVo, DLDI and SW948 HCC cell lines.
Five drug- resistant sublines independently obtained from
each parent line have been characterised for: (1) resistance
pattern; (2) extracellular (IC50ext) and intracelluar (IC50int)
DOX concentration inhibiting cell growth of 50%; (3) DOX
efflux kinetic; and (4) mdrl gene products expression.
Materials and methods
Chemicals
Doxorubicin [(DOX), Adriamicina, Farmitalia, Carlo Erba,
Milan, Italy]; vincristine [(VCR), Oncovin, Lilly, Florence,
Italy]; actinomycin D [(ACT-D), Cosmegen, Merck, Sharp,
Rome, Italy]; cis-diamminedichloroplatinum [(CDDP),
Platinex, Bristol, Latina, Italy] were sterilely dissolved in
saline just before use. '4C-doxorubicin ('4C-DOX) (specific
activity 55mCimmol-'); D-1-_4C mannitol (specific activity
59 mCi mmol ') and 3H20 (specific activity 5 mCi ml- ') were
purchased from Amersham (Buckinghamshire, UK).
Cell lines
LoVo, DLD1 and SW948 HCC cell lines were obtained from
the American Type Culture Collection (Rockville, MD). Cell
lines were propagated in F12 (LoVo) or RPMI 1640 (DLD1
and SW948) supplemented with 10% heat-inactivated fetal
calf serum (FCS) (Seralab, Sussex, UK), I mM Napyruvate,
50 igml-' streptomycin and 50 unitsml-' penicillin G. Cell
cultures were incubated at 37°C in a humidified atmosphere
of 5% CO2 and 95% air.
Cytotoxicity tests
Cytotoxic effects of pharmacological treatments were deter-
mined by clonogenic assay in liquid medium after about 10
days from drug exposure as described (Lorico et al., 1988).
No significant variations were noted for plating efficiencies in
monolayer culture between untreated sensitive parent and
drug-resistant cells. Experimental data obtained by clono-
genic assay were also confirmed by the trypan blue dye
exclusion test, 72 h from cell treatment.
Drug cytotoxicity was calculated as a percentage of cell
survival in drug-treated cultures compared to that in un-
treated controls. Results are reported as drug concentration
inhibiting cell growth of 50% (IC50). IC50 was extrapolated
by linear regression of experimental data.
Selection ofdrug-resistant cell mutants
Drug-resistant sublines were obtained by treating exponen-
tially growing cell cultures in continuous with 100ngml1'
DOX as described (Grandi et al., 1986). The medium was
replaced twice a week with fresh medium containing 100 ng
ml1' DOX. After 5-10 weeks, single colonies of drug-
resistant mutants were harvested with 0.25% trypsin/0.02%
EDTA and singularly cultured for more than 12 months in
the continuous presence of 100 ng ml-' DOX. Drug-resistant
sublines were maintained in presence of 100 ng ml' DOX
until at least 24 h before the experiments.
Northern and Southern analyses
Total cellular RNA and high molecular weight DNA were
extracted from exponentially growing cells by the guanidine
chloride method (Cox, 1968) and the proteinase/phenol-
chloroform method (Maniatis et al., 1982), respectively.
For Northern blots, RNAs were fractionated by electro-
phoresis in a denaturing 1% agarose/6% formaldehyde gel
and transferred to Gene Screen Plus membrane (New Eng-
land Nuclear, Florence, Italy) by electroblotting in 0.025 M
phosphate buffer pH 6.5 (10 Volts overnight and 40 Volts for
1 h). For Southern blot analysis, 10 jLg of DNA were digested
with the EcoRI restriction endonucleases, electrophoresed in
agarose gel and blotted onto a Gene Screen Plus membrane
as described (Southern, 1975).
Filters were prehybridised, hybridised and washed as de-
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scribed (Toffoli et al., 1989b) and exposed to X-ray films with
an intensifying screen at - 80°C. The autoradiographic sig-
nals were quantified by densitometry. Quantification of mdrl
mRNA levels were performed using ,B-actin mRNA levels as
internal standard. mdrl mRNA expression levels were report-
ed in arbitrary units. A value of 10 units for the expression
of 10 fig of total RNA from SW948 cells was assigned.
Probes used were: a 1.2 kb EcoRI fragment derived from
plasmid pHuP170 (kindly provided by W.L. McGuire),
representing a cDNA covering the 3' portion of the human
mdrl gene (Merkel et al., 1989), a human P-actin fragment
(0.7 kb) derived from BamHI-EcoRI digested plasmid
pHFPA-3'UT (Ponte et al., 1983). Probes were 32P-labelled
by multiprime labelling system (Amersham) at specific
activity > 109 counts min-' per 1 fig DNA.
Cytofluorimetric analysis
gpl70 expression was analysed by indirect immunofluores-
cence techniques: 5-10 x I05 cells were fixed in 3.7% formal-
dehyde/PBS (phosphate buffered saline) for 10min at 20°C
and preincubated for 10 min at 20°C in 10% normal goat
serum. MRK16 mouse monoclonal antibody (kindly pro-
vided by Dr Tsuruo) (Hamada & Tsuruo, 1986), diluted to
30 gml-l in PBS containing 1 mM EDTA and 0.1%
saponin, was used as first antibody and FITC-conjugated
goat antimouse IgG (Becton Dickinson, Mountain View,
CA) diluted 1: 20 in PBS/EDTA/saponin was used as second
antibody. Labelled cells were analysed using a Becton
Dickinson FACStar IV. Cells incubated with normal mouse
IgGs as first antibody were used as negative control.
DOX-uptake analysis and determination ofICSOint DOX
Exponentially growing cells, 3 x 106 in 10 ml medium, were
seeded in 90 mm petri dishes (Falcon, Milan, Italy) and
incubated overnight at 37C. After removing culture medium,
cells were incubated for 1.5 h at 37°C with fresh medium
containing different concentrations of '4C-DOX. Radioactive
medium was subsequently withdrawn and petri dishes were
chilled on ice and quickly washed 3 times with ice-cold saline
solution. Cells were harvested by trypsin treatment and
counted using an emocytometer. '4C-DOX uptake was deter-
mined by liquid scintillation counting. Cytotoxic effect of
drug treatments was determined on replicate petri dishes.
Cells size was determined using 3H20 and D-1-'4C manni-
tol as described (Long & Stringfellow, 1988). Intracellular
drug concentration was calculated by dividing the intracellu-
lar drug content by the cell volume.
The intracellular DOX concentration inhibiting cell growth
of 50% (ICSOint DOX) was determined after exposing the
cells for 1.5 h to the external drug concentration inhibiting
cell growth of 50% (IC5Oext DOX).
DOX-efflux analysis
Exponentially growing cells, 3 x I0 in 10 ml medium, were
seeded in 90 mm petri dishes and incubated overnight at
37°C. After removal of culture medium, cells were incubated
at 37°C for 1.5 h with fresh medium containing '4C-DOX. Following incubation the medium was discarded and the cells
were quickly washed in a saline solution prewarmed at 37°C, then prewarmed DOX-free medium was added and the plates
were incubated at 37°C. Retention of '4C-DOX in the cells
was determined at various time points (1.5-60min) using three petri dishes for each time point, as described for drug- uptake studies. Efflux data are expressed as percentages of
the drug retained at each time point relative to drug retained
at time point 0 min.
Statistic
For the statistical evaluation of the data, the unpaired Student's test was used.
Results
Chemosensitivity ofparent-HCC cell lines andderived
drug-resistant sublines
Chemosensitivity of LoVo, DLD1 and SW948 parent-cell lines to DOX, VCR, ACT-D and CDDP has been deter-
mined both by clonogenic assay and trypan blue dye ex- clusion test. As shown in Table I, the 3 cell lines were almost equally sensitive to the different drugs tested.
From each parent line five independently derived DOX- resistant sublines were characterised for chemoresistance. All sublines exhibited the MDR phenotype and were more resis-
tant than the parent line to DOX, VCR, ACT-D but not to CDDP (Table II). The increases in chemoresistance to DOX, VCR, ACT-D presented very little variations among the sublines derived from each parent line, but were consistently different among the 3 subline groups. DOX chemoresistance increased about 20 times in LoVo drug-resistant (LoVo-R), about 9 times in DLD1 drug-resistant (DLDI-R) and about 4 times in SW948 drug-resistant (SW948-R) sublines (Table II). SW948-R sublines showed a different profile of resistance
to VCR and ACT-D with respect to DLDI-R and LoVo-R sublines. In fact, SW948-R sublines exhibited a relative
greater increase in resistance to ACT-D than to VCR, whereas this pattern was inverted in LoVo-R and DLDI-R sublines (Table II).
mdrl mRNA transcription level andgpl70 expression
Expression level of mdrl mRNA was determined by North-
Table I Sensitivity of the human colon carcinomas cell lines to various antitumour
agents
(IC50 ngml-/)a
Cell line DOX ACT-D VCR CDDP
SW948 23.36 (2.77)b 10.22 (±2.62) 50.43 (±5.39) 478.30 (±64.51)
22.87 (1.18)c 14.02 (1.17) 53.97 (9.60) 503.02 (11.62) DLDI 22.25 (±3.40) 10.12 (±3.57) 49.87 (±6.84) 543.99 (±77.04)
23.86 (±3.91) 12.97 (±3.82) 56.31 (±8.97) 642.98 (±59.24) LoVo 20.11 (±4.58) 11.62 (±2.29) 51.32(±4.41) 401.75 (132.00)
25.29 (± 2.04) 13.25 (±4.73) 57.75 (± 6.88) 469.75 (±63.02)
aExtracellular dose inhibiting cell growth of 50% (IC50). Data are from at least three experiments, each done in triplicate. bThe upperconcentrations refer to clonogenic assay, cthe lower ones to the trypan blue dye exclusion test. Cells were exposed to the drug for 24 h.MDR PHENOTYPE IN HUMAN COLON CANCER CELL LINES 53
Table II Cross resistance pattern of MDR sublines with various
antitumour agents
DOX
1
4.2b
4.3b
3.2b
4.5b
4.5b
8.6b
8.8b
9.4b
10.4b
ILlb
111
22.7b
20.0b
22.5b
21.1b
19.3b
Relative resistance'
ACT-D VCR
1 1
ND 1.9b
3.8b 1.8b
3.9b ND
5.lb 2.lb
4.9b 20b
2.8b
ND
3.2b
4.8b
4.1b
8.6b
8.2b
7.3b
5.9b
8.0b
4.1"
ND
4.7b
7.8b
6.8b
14.3b
11.1b
15.3b
12.6b
10.3b
CDDP
ND
1.4
ND
1.4
1.5
1.2
1.1
ND
1.1
1.0
0.82
0.64
0.84
1.02
0.98
aRelativeresistance istheratioofIC50forresistantcellstreatedwith a
particular drug for 24 h to the IC50 for sensitive cells treated with the
same agent for 24 h. Data were obtained from themean ofatleast three
experiments each done in triplicate, using the clonogenic assay.
bIndicates when IC50 of resistant lines was statistically different, by
Student's test, from IC50 of sensitive lines (P<0.01). ND, not
determined.
ern analysis. SW948, DLD1 and LoVo cell lines expressed
10, 16 and 36 mdrl mRNA units, respectively. mdrl mRNA
expression level increased in all drug-resistant sublines by a
roughly identical factor, becoming about 10 times greater
than that expressed by the respective parent cell line (Figure
1). The increased mdrl mRNA expression in all LoVo-R
sublines may have been consequent upon gene amplification;
each subline showed, in fact, 4-5 mdrl gene copies per
aploid genome (data not shown). DLD1-R and SW948-R
sublines presented neither gene amplification nor rearrange-
ment (data not shown).
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Figure 1 Northern hybridisation of RNA from SW948-R,
DLD1-R, LoVo-R resistant clones and parent-cell lines. Each
lane contains 10 g of total cellular RNA. After mdrl hybridisa-
tion, filters were rehybridised with a human P-actin probe as
control for RNA loading. mdrl mRNA units were calculated
from the area under the densitometric peaks for the mdrl signals
normalised by P-actin signals.
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Figure 2 Flow cytometric profiles of drug-resistant sublines. Shown is one representative chemoresistant subline (SW948-R-5;
DLD1-R-6 and LoVo-R-l) obtained from SW948, DLD1 and LoVo parent-cell line, respectively. A, cells incubated with
non-immune mouse IgGs as negative control and FITC-goat antimouse IgGs (Chemoresistant sublines gave similar results); B and
C, cells incubated with MRK16 mouse monoclonal antibody and FITC-goat antimouse IgGs. The log fluorescence intensity was
plotted on the x-axis against the relative cell number on the y-axis.
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Cytofluorimetric analyses showed that the increased mdrl
mRNA expression levels observed in drug-resistant sublines
were associated with a concomitant increase in gpl70 expres-
sion (Figure 2).
Transmembrane drug equilibria and intracellular equitoxic drug
concentrations
Parent-cell lines and drug-resistant sublines were analysed for
transmembrane DOX equilibria to ascertain whether the
enhanced mdrl gene expression in the MDR sublines might
completely explain their increased drug resistance. Analyses
were performed on 2, randomly chosen, MDR sublines for
each parent-cell line: LoVo-R-l and LoVo-R-2, DLDI-R-6
and DLDI-R-8, SW948-R-5 and SW948-R-6. Intracellular
DOX accumulation was determined after 1.5 h of continuous
cell exposure to the drug, at which time the steady-state in
transmembrane drug equilibria was completely established
(data not shown).
As shown in Figure 3, after exposure to the same extracel-
lular DOX concentrations, the corresponding intracellular
drug concentrations were very similar within the 3 parent-cell
lines and SW948-R sublines. On the contrary, DOX accumu-
lations decreased by about 50-60% in DLD1-R and
60-70% in LoVo-R sublines, as compared to the parent
cells.
To determine whether the MDR phenotype in drug-resis-
tant sublines is consequent upon increased intracellular resis-
tance to the drug, the intracellular DOX concentration caus-
ing a 50% inhibition of cell growth (ICSOint DOX) was
established. The three parent-cell lines, that had a similar
chemosensitivity to extracellular DOX concentrations (Table
I), displayed also a similar intracellular sensitivity to the drug
(Table III). In contrast, although the extracellular drug con-
centrations inhibiting cell growth of 50% (IC50ext DOX)
were different among the three subsets MDR sublines, their
respective ICSOint DOX were similar. All MDR sublines
exhibited, in fact, an ICSOint DOX about 3.5 times greater
than the ICSOint DOX of parent-cell lines (Table III). There-
fore the intracellular drug resistance of the three groups of
MDR sublines increased uniformly, in spite of different mdrl
mRNA expression levels exhibited. This property was also
confirmed in a wide range of intracellular drug concentra-
tions (Figure 4).
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Table III Extracellular and intracellular DOX concentrations
inhibiting cell growth of 50% (IC50) in sensitive and resistant cells
ICSOext DOXa ICSOint DOXb (pmol
Cell line (ngml-') DOX 10-6 cells) Res/Sens
SW948 350 146.73±21.32 1
SW948-R-5 1400 547.57± 54.51 3.73
SW948-R-6 1400 581.20± 127.36 3.96
DLDI 350 160.23± 15.87 1
DLDI-R-6 3400 553.66±94.93 3.46
DLDI-R-8 3600 579.95±87.10 3.62
LoVo 350 171.30± 18.04 1
LoVo-R-l 7500 625.28± 105.64 3.65
LoVo-R-2 6600 600.34± 80.36 3.50
aExtracellular DOXconcentrationinhibitingcellgrowthof50% after
1.5 hexposure to DOX. Eachvalue represents themean± s.d. ofatleast
five independent experiments. bCorresponding intracellular DOX con-
centration (IC50int DOX).
IC50int resistant subline
IC50int sensitive parent-cell line
DOX-efflux kinetic
Efflux kinetic analyses performed on drug-sensitive parent-
cell lines and drug-resistant sublines indicated that decreases
of intracellular DOX accumulation in DLDl-R and LoVo-R
sublines were consequent upon an increased drug efflux
(Figure 5). Since the metabolic inhibitor Na azide eliminated
the differences in transmembrane drug equilibria observed
(data not shown), it is assumed that drug efflux was due to
an energy-dependent biochemical mechanism. No significant
differences in DOX efflux were observed among SW948,
DLDI and LoVo drug-sensitive and SW948-R drug-resistant
cell lines.
Discussion
The present study has indicated that MDR phenotype, at
least in the HCC cell lines studied, is a multifactorial pheno-
menon determined by different and possibly independent
biochemical mechanisms which cooperate, in amounts vary-
ing from cell line to cell line, in conferring cellular chemo-
resistance. The analyses on transmembrane DOX equilibria
Cell lines
Figure 3 Intracellular DOX concentrations in SW948, DLD1 and LoVo sensitive and resistant cells. Intracellular DOX accumula-
tions were determined after treating cells for 1.5 h with the extracellular DOX concentrations indicated dn the right of the figure.
Intracellular drug concentrations (expressed as pmol DOX 10-6 cells) were obtained by normalising DOX accumulations for the
cell size of DLD1 sensitive cell line at which a value of 1 was assigned. Ratios between the size of DLDI sensitive cell line and
SW948, SW948-R-5 and SW948-R-6 were 1.21, 0.89 and 0.91, respectively; the ratios between DLD1 and DLD1-R-6 and
DLD1-R-8 were 1.07 and 1.10, respectively; the ratios between DLDI and LoVo, LoVo-R-1 and LoVo-R-2 were 0.87, 0.83 and
0.80, respectively. *indicates when intracellular DOX concentrations in resistant sublines were significatively different from the
parent cell line (P<0.01) after treatment with the same extracellular DOX concentration. Bars, s.d.MDR PHENOTYPE IN HUMAN COLON CANCER CELL LINES 55
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Figure 4 Effect of intracellular DOX concentration on cell sur-
vival of SW948-R-5 (O), DLDI-R-6 (A) and LoVo-R-I (0)
sublines. Points, mean from 4 to 7 determinations.
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Figure 5 Efflux of '4C-DOX from sensitive and resistant cells. O
SW948-R-5, A DLDI-R-6, 0 LoVo-R-I cell lines; dark sym-
bols: parent cell lines; open symbols: resistant sublines. Data are
referred as percentage of DOX retained in cells with respect to
time 0 (100%). Points, mean of five experiments. A statistically
significant difference between resistant and parent cell lines is
indicated in the figure with asterisks (*P<0.05; **P<0.01).
and equitoxic intracellular DOX accumulations have shown
that the biochemical phenoma, which determine multidrug-
resistance, exert their effect on different cellular compart-
ments. The first mechanism acts at the plasma-membrane
level and affects drug transmembrane equilibria determining
reduced intracellular drug accumulation. Said mechanism
may be ascribed to the biochemical activity of the mdrl gene
product, the gpl70 (Chen et al., 1986), as indicated by the
DOX efflux and mdrl gene expression studies in LoVo-R and
DLD1-R sublines. With respect to the parent-cell lines, both
LoVo-R and DLD1-R variants showed, in fact, increased
mdrl gene transcriptional and translational activities deter-
mining an increased DOX efflux and reduced drug uptake in
the cells. This suggests that in LoVo-R and DLD1-R sub-
lines, higher levels of mdrl gene products confer a selective
advantage during drug exposure. On the contrary, we cannot
at present explain the biological meaning of enhanced mdrl
mRNA and gp170 expression observed in SW948-R sublines.
We have been unable to determine any reduction in intracel-
lular DOX accumulation even when SW948-R sublines were
treated with the extracellular DOX concentration used for
their selection from the parent line (100ngml-'). This sug-
gests that relatively low levels of mdrl expression, such as
those displayed by the three parent-cell lines and SW948-R
sublines, do not affect drug-transmembrane equilibria. Alter-
natively, variations in drug-transmembrane equilibria in
SW948-R might be smaller than in LoVo-R or DLD1-R
variants and not measurable with our experimental proce-
dures (Deffie et al., 1988), or the mdrl basic function (still
undefined) in parent cells may be augmented in SW948-R
variants without affecting drug-transmembrane transport, as
suggested by Gerlach et al. (1986).
The second mechanism, which confers drug-resistance to
the HCC MDR sublines exerts its effect at intracellular level,
as evidenced by the greater intracellular DOX concentration
needed to obtain a 50% cell growth inhibition (IC5Oint
DOX) in all drug-resistant sublines investigated. This finding
implies that biochemical mechanisms, independent of trans-
membrane drug equilibria, increase their effect in MDR sub-
lines. Our data strongly support previously reported results
on MDR small lung cancer cell lines obtained by Cole et al.
(1989) and Reeve et al. (1989) which also indicated that at
least two different biochemical phenomena lead to MDR.
The first one involves gp170 whereas the second is not at
present identifiable at molecular level. Possibly, this second
drug-resistance mechanism is the only active one in SW948-R
sublines. Two gene systems are presently thought to be
related to intracellular drug resistance: topoisomerases (Pom-
mier et al., 1986) and glutathione-S-transferase (Kano et al.,
1987). These cellular enzymes are involved in DNA confor-
mational modification and cellular detoxification, respective-
ly. The peculiar pattern of cross resistance presented by
SW948-R sublines may be useful in elucidating which of
these gene systems, if any, is implicated in the intracellular
drug-resistance mechanism.
Finally, in all drug-resistant sublines analysed, each drug-
resistance mechanism increased its effect, as compared to the
parent cell line, by a specific and constant factor. In fact,
mdrl gene expression level increased about 10 times and the
intracellular drug resistance about 3.5 times. At present, we
do not know the molecular basis of such a phenomenon,
however the constancy of the factorial occurrence looks very
promising and deserving of further studies.
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